David Cullinane (Waterford, Sinn Fein) | Oireachtas source

I was going to get to that in a few minutes. Epidiolex is important for epilepsy patients. I know it has been licensed and is going through the reimbursement process. I hope it will be successful and make a difference. I am trying to get a sense of how successful this programme will be. If there is only going to be one product this year we do not know how many products will be available next year. Mr. Flanagan said some modelling has been done but we do not really know how many of these products will be prescribed to patients. At this point it is hard to get a handle on how successful the MCAP programme will be. I would have imagined it was anticipated that more products would have been online by now and more products would have been not just on the Schedule but available for prescription. Is it fair to say it is a bit disappointing that for whatever reason, and obviously it is down to the companies themselves that have to engage, only one product will be available as a start for a programme as important as this is? We do not know how many products will be available next year and we do not know how many patients will be prescribed the drug this year or next year. This is not painting a good picture. There is not much information, it would seem, that I can give to the public or that will be given to the public arising from this session.